AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30642308 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) with continued escitalopram until day 28
Number of subjects: 192
Study 30642308 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 192
Study 28545804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 50 µg once daily in the evening
Number of subjects: 60
Study 28545804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28545804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 50 µg
Number of subjects: 60
Study 28545804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Number of subjects: 60
Study 25884803 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management (TCM) programme
Number of subjects: 80
Study 25884803 — intervention group
Group type: COMPARATOR
Intervention: Teach as normal (control)
Number of subjects: 80
Study 23712210 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-ERT (Cognitive Behavioral Therapy enriched with Emotion Regulation Training)
Number of subjects: 432
Study 23712210 — intervention group
Group type: COMPARATOR
Intervention: CBT (Cognitive Behavioral Therapy)
Number of subjects: 432
Study 19616860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-tracked group in a community scheme led by an exercise instructor
Number of subjects: 100
Study 19616860 — intervention group
Group type: COMPARATOR
Intervention: Conventional Phase III hospital group
Number of subjects: 100
Study 19616860 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase IV attendees
Number of subjects: 100
Study 18955525 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-80 50 mg
Number of subjects: 48
Study 18955525 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-80 100 mg
Number of subjects: 48
Study 18955525 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-80 200 mg
Number of subjects: 48
Study 18955525 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-80 (all dosages)
Number of subjects: 48
Study 17175106 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat
Number of subjects: 98
Study 17175106 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (SD-Ag)
Number of subjects: 98
Study 15033398 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 70 diaphragm without clinician fitting
Number of subjects: 0
Study 15033398 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based fitting (considering parity, body weight, etc.)
Number of subjects: 0
Study 11320586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients
Number of subjects: 50
Study 11320586 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study 9272758 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day)
Number of subjects: 8
Study 9272758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8174716 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) plus oral contraceptive (OC) containing cyproterone acetate
Number of subjects: 32
Study 8174716 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (LA) alone
Number of subjects: 32
Study 29283797 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep assessments (questionnaire)
Number of subjects: 59
Study 29283797 — intervention group
Group type: COMPARATOR
Intervention: Objective sleep assessments (actigraphy)
Number of subjects: 59
Study 27087213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunshine exposure on weekdays
Number of subjects: 43771
Study 27087213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunshine exposure on weekends
Number of subjects: 43771
Study 27087213 — intervention group
Group type: COMPARATOR
Intervention: Factors influencing sunshine exposure on weekdays
Number of subjects: 43771
Study 27087213 — intervention group
Group type: COMPARATOR
Intervention: Factors influencing sunshine exposure on weekends
Number of subjects: 43771
Study 27087213 — intervention group
Group type: COMPARATOR
Intervention: Multivariate logistic regression analysis
Number of subjects: 43771
Study 25712537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate/17β‐estradiol (NOMAC/E2)
Number of subjects: 3522
Study 25712537 — intervention group
Group type: COMPARATOR
Intervention: Drospirenone/ethinylestradiol (DRSP/EE)
Number of subjects: 3522
Study 22925421 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25%
Number of subjects: 106
Study 22925421 — intervention group
Group type: COMPARATOR
Intervention: normal saline 0.9% (NS)
Number of subjects: 106
Study 20627691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride (cold)
Number of subjects: 0
Study 20627691 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated Neuropen (sharp)
Number of subjects: 0
Study 20627691 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized monofilament 10 g (pressure)
Number of subjects: 0
Study 20627691 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotip stroking (light touch)
Number of subjects: 0
Study 20627691 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament stroking (light touch)
Number of subjects: 0
Study 20627691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton wool (light touch)
Number of subjects: 0
Study 18692890 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicate metaphors
Number of subjects: 0
Study 18692890 — intervention group
Group type: COMPARATOR
Intervention: Literal sentences
Number of subjects: 0
Study 16723364 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily)
Number of subjects: 741
Study 16723364 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin plus metronidazole (ofloxacin 400 mg twice daily + metronidazole 500 mg twice daily)
Number of subjects: 741
Study 12729115 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-retained total knee replacement
Number of subjects: 129
Study 12729115 — intervention group
Group type: COMPARATOR
Intervention: PCL-resected total knee replacement
Number of subjects: 129
Study 11049904 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 500
Study 11049904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 500
Study 11049904 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 500
Study 11049904 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 500
Study 8971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days
Number of subjects: 121
Study 8971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days
Number of subjects: 121
Study 8971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days
Number of subjects: 121
Study 8971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days
Number of subjects: 121
Study 8971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days
Number of subjects: 121
Study 8971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days
Number of subjects: 121
Study 8971305 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients remaining H. pylori-positive)
Number of subjects: 121
Study 8971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients cured of H. pylori infection
Number of subjects: 121
Study 1595789 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate (400 micrograms intranasal three times daily for 6 months)
Number of subjects: 71
Study 1595789 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 71
Study 1595789 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate
Number of subjects: 71
Study 2996310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering diet
Number of subjects: 16
Study 2996310 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 2996310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high vs low cholesterol reduction)
Number of subjects: 16
Study 30346481 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice daily for ≤3 years (minimum 1 year unless recurrence, second primary malignancy, significant toxicity, or consent withdrawal)
Number of subjects: 724
Study 30346481 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 724
Study 30346481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 25765462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 2 g twice daily
Number of subjects: 136
Study 25765462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 25765462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 136
Study 24991045 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttermilk drink containing 1.5 lutein-rich egg yolks daily for 1 year
Number of subjects: 101
Study 24991045 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 101
Study 24991045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol absorbers consuming the lutein-enriched drink
Number of subjects: 101
Study 24991045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol absorbers
Number of subjects: 101
Study 24991045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol absorbers, cholesterol synthesizers, and average campesterol-to-lathosterol ratio participants
Number of subjects: 101
Study 22271239 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 120
Study 22271239 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendant presence
Number of subjects: 120
Study 19692186 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction
Number of subjects: 0
Study 19692186 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 18384442 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1000-mug dose via dry powder inhaler)
Number of subjects: 22
Study 18384442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (1000-mug dose via dry powder inhaler)
Number of subjects: 22
Study 15938587 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaVite (n = 20)
Number of subjects: 40
Study 15938587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 11902619 — intervention group
Group type: EXPERIMENTAL
Intervention: Actions taken after positive or absent prior outcomes
Number of subjects: 0
Study 11902619 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactions following negative prior outcomes
Number of subjects: 0
Study 11902619 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential effects for regret and disappointment in Experiment 4
Number of subjects: 0
Study 9915317 — intervention group
Group type: EXPERIMENTAL
Intervention: Target effect compartment concentration of propofol (5.4 microg/ml)
Number of subjects: 20
Study 9915317 — intervention group
Group type: COMPARATOR
Intervention: Target central compartment concentration of propofol (5.4 microg/ml)
Number of subjects: 20
Study 7752177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (14 patients) switched to low-salt diet for 4 weeks
Number of subjects: 30
Study 7752177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (16 patients) switched to high-salt diet for 4 weeks
Number of subjects: 30
Study 2261927 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-vision endoscopic urethrotomy (cold-knife incision at 12 o'clock)
Number of subjects: 30
Study 2261927 — intervention group
Group type: COMPARATOR
Intervention: Internal urethrotomy plus Nd‐YAG laser
Number of subjects: 30
Study 7005134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg, two days a week, for eight weeks
Number of subjects: 32
Study 7005134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31266489 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 15.6 μg twice daily
Number of subjects: 867
Study 31266489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study 29724638 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 9.1 mg
Number of subjects: 357
Study 29724638 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular aripiprazole 9.75 mg
Number of subjects: 357
Study 27082959 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP infiltration with liposomal bupivacaine
Number of subjects: 318
Study 27082959 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural analgesia with plain bupivacaine
Number of subjects: 318
Study 27082959 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 318
Study 25068233 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy (20-30 mg/day) for 6 months associated with dietary supplement (twice a day)
Number of subjects: 48
Study 25068233 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin therapy (20-30 mg/day) for 6 months
Number of subjects: 48
Study 22193433 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U BTX‐A
Number of subjects: 20
Study 22193433 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U BTX‐A
Number of subjects: 20
Study 20645486 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil, propofol, and sevoflurane
Number of subjects: 100
Study 20645486 — intervention group
Group type: COMPARATOR
Intervention: remifentanil, propofol, and rocuronium
Number of subjects: 100
Study 18336921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes (TT)
Number of subjects: 0
Study 18336921 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15978972 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 120 mg/day
Number of subjects: 37
Study 15978972 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 160 mg/day
Number of subjects: 37
Study 12544981 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 0
Study 10569171 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier Ophthalmology Drape (Group A)
Number of subjects: 60
Study 10569171 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri Drape 1062 (Group B)
Number of subjects: 60
Study 10569171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton drape + Steri Drape 1024 (Group C)
Number of subjects: 60
Study 10569171 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 60
Study 9213879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride (100 mg twice a day for 10 days)
Number of subjects: 68
Study 9213879 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-steroidal anti-inflammatory drugs for rheumatoid arthritis, paracetamol for OA and vertebrogen syndrome)
Number of subjects: 68
Study 1927946 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin, 100 mg/day
Number of subjects: 216
Study 1927946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 6350247 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate feeding (glucose polymer solution)
Number of subjects: 10
Study 6350247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31557585 — intervention group
Group type: COMPARATOR
Intervention: Home exercises (HOME)
Number of subjects: 146
Study 31557585 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation (REHAB)
Number of subjects: 146
Study 31557585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HOME and REHAB)
Number of subjects: 146
Study 30782714 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 0
Study 30782714 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 0
Study 27461092 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (animated short films)
Number of subjects: 40
Study 27461092 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 40
Study 25029557 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 31
Study 25029557 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic solution (Gatorade®)
Number of subjects: 31
Study 25029557 — intervention group
Group type: COMPARATOR
Intervention: Control (no hydration)
Number of subjects: 31
Study 23629739 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring without nurse support
Number of subjects: 237
Study 23629739 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring weekly after 1 month
Number of subjects: 237
Study 23629739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no monitor offered)
Number of subjects: 237
Study 22210421 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 36
Study 22210421 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 19808309 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate I LVAD implantation at centers performing <=4 DT implants
Number of subjects: 377
Study 19808309 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate I LVAD implantation at centers performing >9 DT implants
Number of subjects: 377
Study 17693215 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week RAS music-movement exercise intervention (n = 16)
Number of subjects: 33
Study 17693215 — intervention group
Group type: COMPARATOR
Intervention: Referral information about available usual care services (n = 17)
Number of subjects: 33
Study 15155328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg succinylcholine
Number of subjects: 115
Study 15155328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg succinylcholine
Number of subjects: 115
Study 15155328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 115
Study 15155328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg succinylcholine
Number of subjects: 115
Study 15155328 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 115
Study 10986213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10986213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 39
Study 10986213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 39
Study 10986213 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 39
Study 8841892 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR (Hard Tissue Replacement Synthetic Bone)
Number of subjects: 1
Study 8841892 — intervention group
Group type: COMPARATOR
Intervention: FDBA (freeze-dried bone allograft)
Number of subjects: 1
Study 1994867 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol treatment in primary Raynaud's phenomenon
Number of subjects: 43
Study 1994867 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol treatment in systemic sclerosis
Number of subjects: 43
Study 1994867 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 43
Study 6500169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (7 mg/kg of body-weight)
Number of subjects: 28
Study 6500169 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (15 mg/kg of body-weight)
Number of subjects: 28
Study 31508504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradoriids with varying limb morphologies and limb-tagmosis patterns
Number of subjects: 3
Study 31508504 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophyletic stem-euarthropod group
Number of subjects: 3
Study 31508504 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative solution of polyphyletic bradoriids
Number of subjects: 3
Study 31508504 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolutionary convergence
Number of subjects: 3
Study 29886423 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Nifedipine slow release 30 mg
Number of subjects: 55
Study 29886423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 29886423 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Nifedipine
Number of subjects: 55
Study 29886423 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure
Number of subjects: 55
Study 1463157 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 to 0.08 mg intrathecal morphine
Number of subjects: 30
Study 1463157 — intervention group
Group type: COMPARATOR
Intervention: Control group without morphine
Number of subjects: 30
Study 22721546 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to medication
Number of subjects: 140
Study 22721546 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence to medication
Number of subjects: 140
Study 22721546 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 140
Study 21702271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory cleft lip surgery under loco-regional anaesthesia
Number of subjects: 80
Study 21702271 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cleft lip surgery under general anaesthesia
Number of subjects: 80
Study 18766096 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic condition (7% CO2)
Number of subjects: 20
Study 18766096 — intervention group
Group type: COMPARATOR
Intervention: Normocapnic condition (5% CO2)
Number of subjects: 20
Study 18766096 — intervention group
Group type: COMPARATOR
Intervention: Hypocapnic condition (2% CO2)
Number of subjects: 20
Study 15974833 — intervention group
Group type: EXPERIMENTAL
Intervention: PON1 192 AA and PON1 55 MM genotypes
Number of subjects: 213
Study 15974833 — intervention group
Group type: EXPERIMENTAL
Intervention: PON1 192 BB and PON1 55 LL genotypes
Number of subjects: 213